R B Walter1, S A Buckley, E White. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. rwalter@fhcrc.org
Abstract
BACKGROUND: Conflicting evidence exists on the relationship between physical activity (PA) and incident hematologic malignancies. Herein, we used a large cohort study to examine this association. PATIENTS AND METHODS: Sixty-five thousand three hundred twenty-two volunteers aged 50-76 years were recruited from 2000 to 2002. Incident hematologic malignancies (n = 666) were identified through 2009 by linkage to the Surveillance, Epidemiology, and End Results cancer registry. Hazard ratios (HRs) for hematologic malignancies associated with PA averaged over 10 years before baseline were estimated with Cox proportional hazards models, adjusting for factors associated with hematologic cancers or PA. RESULTS: There was a decreased risk of hematologic malignancies associated with PA (HR = 0.66 [95% confidence interval, 95% CI 0.51-0.86] for the highest tertile of all PA, P-trend = 0.005, and HR = 0.60 [95% CI 0.44-0.82] for the highest tertile of moderate/high-intensity PA, P-trend = 0.002). These associations were strongest for myeloid neoplasms (HR = 0.48 [95% CI 0.29-0.79] for the highest tertile of all PA, P-trend = 0.013, and HR = 0.40 [95% CI 0.21-0.77] for the highest tertile of moderate/high-intensity PA, P-trend = 0.016). There were also significant associations between PA and chronic lymphocytic leukemia/small lymphocytic lymphoma or other mature B-cell lymphomas except plasma cell disorders. CONCLUSIONS: Our study offers the strongest epidemiological evidence, to date, to suggest an association between regular PA and dose-dependent risk reduction for most hematologic malignancies, particularly myeloid neoplasms.
BACKGROUND: Conflicting evidence exists on the relationship between physical activity (PA) and incident hematologic malignancies. Herein, we used a large cohort study to examine this association. PATIENTS AND METHODS: Sixty-five thousand three hundred twenty-two volunteers aged 50-76 years were recruited from 2000 to 2002. Incident hematologic malignancies (n = 666) were identified through 2009 by linkage to the Surveillance, Epidemiology, and End Results cancer registry. Hazard ratios (HRs) for hematologic malignancies associated with PA averaged over 10 years before baseline were estimated with Cox proportional hazards models, adjusting for factors associated with hematologic cancers or PA. RESULTS: There was a decreased risk of hematologic malignancies associated with PA (HR = 0.66 [95% confidence interval, 95% CI 0.51-0.86] for the highest tertile of all PA, P-trend = 0.005, and HR = 0.60 [95% CI 0.44-0.82] for the highest tertile of moderate/high-intensity PA, P-trend = 0.002). These associations were strongest for myeloid neoplasms (HR = 0.48 [95% CI 0.29-0.79] for the highest tertile of all PA, P-trend = 0.013, and HR = 0.40 [95% CI 0.21-0.77] for the highest tertile of moderate/high-intensity PA, P-trend = 0.016). There were also significant associations between PA and chronic lymphocytic leukemia/small lymphocytic lymphoma or other mature B-cell lymphomas except plasma cell disorders. CONCLUSIONS: Our study offers the strongest epidemiological evidence, to date, to suggest an association between regular PA and dose-dependent risk reduction for most hematologic malignancies, particularly myeloid neoplasms.
Authors: Theresa H M Keegan; Sally L Glaser; Christina A Clarke; Ronald F Dorfman; Risa B Mann; Joseph A DiGiuseppe; Ellen T Chang; Richard F Ambinder Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-06 Impact factor: 4.254
Authors: James R Cerhan; Leslie Bernstein; Richard K Severson; Scott Davis; Joanne S Colt; Aaron Blair; Patricia Hartge Journal: Cancer Causes Control Date: 2005-12 Impact factor: 2.506
Authors: Elza M S Silveira; Mariana F Rodrigues; Maurício S Krause; Damiana R Vianna; Bibiana S Almeida; Juliane S Rossato; Lino P Oliveira; Rui Curi; Paulo I Homem de Bittencourt Journal: Cell Biochem Funct Date: 2007 Jan-Feb Impact factor: 3.685
Authors: Brenda M Birmann; Edward Giovannucci; Bernard Rosner; Kenneth C Anderson; Graham A Colditz Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-07 Impact factor: 4.254
Authors: Dean Ornish; Mark Jesus M Magbanua; Gerdi Weidner; Vivian Weinberg; Colleen Kemp; Christopher Green; Michael D Mattie; Ruth Marlin; Jeff Simko; Katsuto Shinohara; Christopher M Haqq; Peter R Carroll Journal: Proc Natl Acad Sci U S A Date: 2008-06-16 Impact factor: 11.205
Authors: Anne McTiernan; Christine M Friedenreich; Peter T Katzmarzyk; Kenneth E Powell; Richard Macko; David Buchner; Linda S Pescatello; Bonny Bloodgood; Bethany Tennant; Alison Vaux-Bjerke; Stephanie M George; Richard P Troiano; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Antonello Sica; Caterina Sagnelli; Alfonso Papa; Massimo Ciccozzi; Evangelista Sagnelli; Armando Calogero; Erika Martinelli; Beniamino Casale Journal: Int J Environ Res Public Health Date: 2020-03-16 Impact factor: 3.390
Authors: Gwynivere A Davies; Christopher Strader; Richa Chibbar; Stefania Papatheodorou; Adam A Dmytriw Journal: BMC Cancer Date: 2020-10-06 Impact factor: 4.430